These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22481019)

  • 1. LASP-1, a novel urinary marker for detection of bladder cancer.
    Ardelt P; Grünemay N; Strehl A; Jilg C; Miernik A; Kneitz B; Butt E
    Urol Oncol; 2013 Nov; 31(8):1591-8. PubMed ID: 22481019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
    Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of hematuria and infection on diagnostic accuracy of urinary LASP1: a new biomarker for bladder carcinoma.
    Butt E; Ebbing J; Bubendorf L; Ardelt P
    Biomark Med; 2017 Apr; 11(4):347-357. PubMed ID: 28290211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LIM and SH3 protein 1, a promoter of cell proliferation and migration, is a novel independent prognostic indicator in hepatocellular carcinoma.
    Wang H; Li W; Jin X; Cui S; Zhao L
    Eur J Cancer; 2013 Mar; 49(4):974-83. PubMed ID: 23084841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
    Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
    Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H; Kor K; Djalali M
    Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
    Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
    Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
    Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
    Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
    Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
    Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
    Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation.
    Grunewald TG; Kammerer U; Winkler C; Schindler D; Sickmann A; Honig A; Butt E
    Br J Cancer; 2007 Jan; 96(2):296-305. PubMed ID: 17211471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1.
    Zhao L; Wang H; Liu C; Liu Y; Wang X; Wang S; Sun X; Li J; Deng Y; Jiang Y; Ding Y
    Gut; 2010 Sep; 59(9):1226-35. PubMed ID: 20660701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
    Parekattil SJ; Fisher HA; Kogan BA
    J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.
    Pariente JL; Bordenave L; Michel P; Latapie MJ; Ducassou D; Le Guillou M
    J Urol; 1997 Aug; 158(2):338-41. PubMed ID: 9224298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LIM and SH3 domain protein 1 (LASP-1) overexpression was associated with aggressive phenotype and poor prognosis in clear cell renal cell cancer.
    Yang F; Zhou X; Du S; Zhao Y; Ren W; Deng Q; Wang F; Yuan J
    PLoS One; 2014; 9(6):e100557. PubMed ID: 24955835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of urine-based tumour markers in bladder cancer surveillance.
    Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
    Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.